Latest ArticlesMesenchymal stem cells(MSCs) are distributed widely in the human body. MSCs have powerful self-renewal ability, pluripotency, and immunomodulation property. Due to the damaged tissue and tumor site tropism, MSCs that express antibodies have potential applications in tumor therapy. However, the low efficiency of MSC transfection restricts their application. This study optimized four transfection methods for human umbilical cord blood-derived MSCs. The results showed that with the optimal packaging conditions[m(DNA)∶m(Lipo)=1∶2, m(vector)∶m(psPAX2)∶m(VSVG)=3∶2∶1], lentivirus produced by three-plasmid system could infect MSCs more efficiently, 50% of MSCs could express target protein successfully. In addition, MSCs expressing two antibodies with different structures, Anti-CD24 and BiTE-Fc, were successfully constructed with the above methods, respectively, providing the research basis for applying MSCs in tumor therapy.
Acacetin(1) is a natural flavone that can prevent atrial fibrillation in vivo and in vitro with high specificity. However, low solubility and short half-life severely of 1 limit its medicinal application. In order to improve its water solubility and enhance oral absorption, two 1 glycosyl prodrugs targeting the intestinal sodium-glucose transporter1(SGLT1) were designed and synthesized. The results of Caco-2 cell transport experiment showed that the permeabilities of the two 1 glycosyl prodrugs were higher than 1. The permeability of the glycosyl prodrug was mediated by SGLT1 and was affected by the efflux of multi-drug resistant proteins. The pharmacokinetics results in rats showed that the cmax values of monosaccharide and disaccharide derivatives of 1 were 5 and 30 times higher than that of 1, respectively. The AUC values of them was 10 and 100 times higher than that of 1, respectively, and the half-lives of both derivatives were extended for about 2 hours. These results indicated that glycosyl modification of 1 could effectively enhance its oral absorption.
The optimal formulation of chlorogenic acid(1) liposomes was developed using a combination of Box-Behnken design and response surface methodology. Subsequently, the liposomes were surface modified with chitosan. The results of transmission electron microscopy revealed that liposomes with or without surface modification were spherical, while the surface modification liposomes displayed a distinct core-shell structure. The average particle sizes of above two liposomes were (185.0±10.8) and (265.0±11.9)nm, respectively, while the ζ potentials were (–18.3±2.1) and(45.6±3.5)mV. The results of in vitro release test indicated that the release behavior of 1 from the unmodified liposomes fit the Higuchi model well, while the chitosan-modified liposomes exhibited a better fit to the Korsmeyer-Peppas model. The improved Franz diffusion cell method was used to investigate the in vitro transdermal performance of the product on mouse skin. The steady-state permeation fluxes of 1 solution, 1 liposomes and chitosan-modified 1 liposomes were 1.77, 0.98 and 0.73 μg·cm–2·h–1, respectively, with skin retention at 36 h of (113.4±7.4), (399.6±5.5), and (519.6±13.1)μg/cm2. These results suggested that chitosan-modified 1 liposomes had lower skin penetration but higher skin retention than those of 1 solution and 1 liposomes, making them a promising candidate for transdermal drug delivery.
Hyaluronic acid(HA) and glycyrrhetinic acid(GA) were chemically bonded to prepare the HA-GA composite with CD44 receptor targeting property, then the polymeric micelles of HA-GA composite were obtained. The pharmaceutical properties and anti-hepatic fibrosis activity in vitro were evaluated by MTT assay and enzyme linked immunosorbent assay. The results showed that the critical micelle concentration of the HA-GA composite was 9.6 μg/mL, the particle size of the polymeric micelles was 217.0 nm, and the GA content was 18.9%. Compared with the GA solution, HA-GA polymeric micelles showed potent cytotoxicity, meanwhile could inhibit the secretion of transforming growth factor β1 by hepatic stellate cells, exhibiting well anti-hepatic fibrosis activity in vitro.
A gel solution was prepared by heating the mixture of gelatin, partially dehydrated sorbitol, glycerin and water. An opacifier and other ingredients were added into above solution to obtain the gelatin film shell. A Box-Behnken design-response surface method was employed to optimize the gelatin film shell with material mobility, equilibrium swelling amount, water vapor permeability, light transmittance, and disintegration time as the dependent variables, and with gelatin grade, the mass ratio of partially dehydrated sorbitol to glycerin, and the proportion of titanium dioxide as the independent variables. The optimal gelatin film shell formulation was as follows: the gelatin strength was 150 g bloom, the mass ratio of partially dehydrated sorbitol to glycerin was 2.3∶10, and the proportion of titanium dioxide to gelatin was 1.18%. Three consecutive batches of gelatin film shell were manufactured based on the optimized formulation. The deviations of actual material mobility values, equilibrium swelling amount, and light transmittance from the predicted values were no more than 1.7%. The inter-batch RSD did not exceed 0.36%. These results indicated that the optimized gelatin film shell formulation had good accurate, reproducible and stability. This study could provide some references to improve the industrialized production of soft capsules.
An UPLC-MS/MS method was established to determine the cycloastragenol(1) in plasma of SD rats and Beagle dogs. 20(S)-Protopanaxadiol was used as an internal standard and methanol was used to precipitate the protein. In addition, the in vivo tests were designed to investigate the pharmacokinetic behavior of 1 in SD rats and Beagle dogs after oral administration or injection of 1. Twenty-four SD rats were randomly divided into four groups, 1 suspension with doses of 1, 3 and 10 mg/kg was given by gavage, and 1 injection with a dose of 1 mg/kg was given intravenously. The results showed that the tmax of 1 suspension of 1, 3 and 10 mg/kg orally administered to SD rats was 0.5 h, the t1/2 was 0.82 - 0.93 h, and the AUC0→t were 190, 602, 1 818 μg·L- 1·h, respectively. The plasma exposure increased linearly with the dosage, and the oral bioavailability was 29.4%. Twelve Beagle dogs were randomly divided into two groups, 1 suspension with a dose of 30 mg/kg was given by gavage and 1 injection with a dose of 1 mg/kg was given intravenously. The results showed that the tmax of 1 suspension was 0.5 h, the t1/2 was 1.26 h, and the AUC0→t was 110 μg·L–1·h. The elimination rate was slightly slower than that of SD rats and the oral bioavailability was 0.5%. This study reported the comparison of the pharmacokinetics of 1 suspension in SD rats and Beagle dogs, which provided a reference for the further study of this drug.
An HPLC-CAD method was established for the determination of seven related substances(2 - 8) in sugammadex sodium(1) bulk drug. The Poroshell 120 SB-C8 column(4.6 mm×150 mm, 2.7 μm) was used, and the analysis was carried out in the linear gradient elution mode with 0.5% formic acid solution as mobile phase A, and methanol as mobile phase B. The flow rate was 0.5 mL/min and the column temperature was 35 ℃. The temperature of the atomizer of the charged aerosol detector(CAD) was 35 ℃, the filtration constant was 3.6 s, and the data acquisition rate was 5 Hz. The results showed that it was linear for 3 in the range of 5 - 300 μg/mL, and it was linear for 1 bulk drug and other related substances in the range of 2 - 40 μg/mL. The LOQs and LODs of 1 - 8 were 0.985 - 1.145 μg/mL and 0.493 - 0.573 μg/mL, respectively. The average recoveries(n=9) of 2 - 8 were 95.6% - 99.4%, with the RSDs of 1.21% -3.32%. This method is accurate, reproducible, and highly precise, which can be used to detect the related substances in 1 bulk drug, and also provides a reliable detection method for the quality control of 1.